TIDMSENS
Sensyne Health PLC
16 October 2018
PRESS RELEASE - RNS REACH
Official product launch of GDm-Health(TM)
Five NHS Trusts have signed contracts to use GDm-Health
Oxford, UK; 16(th) October 2018: Sensyne Health plc (LSE: SENS),
the British clinical AI technology company, today announces the
commercial launch of its GDm-Health(TM) product, the patient
app-to-clinician software system for the management of gestational
diabetes mellitus (GDM).
GDm-Health replaces the traditional paper-based method of
management. The system comprises a smartphone application which
connects to a wireless blood glucose monitor. The woman's blood
glucose measurements, any text-based commentary she wishes to log
and any request for a call back she makes are transmitted directly
to a web-based clinical dashboard for the multi-disciplinary team
at the hospital supervising her care to manage proactively. The
care team can see near real-time data that has been prioritised
through appropriate algorithms and can communicate directly with
patients through the system.
The app has now completed its development following a 2 year
clinical evaluation in the NHS by over 1,000 women, and is
currently available to pregnant women and their midwives at Oxford
University Hospitals NHS Foundation Trust and Royal Berkshire NHS
Foundation Trust. Three additional NHS Trusts will be implementing
GDm-Health in the coming weeks, including Buckinghamshire
Healthcare NHS Trust, Croydon Health Services NHS Trust and Milton
Keynes University Hospital NHS Foundation Trust.
GDm-Health is one of a number of data-driven health technology
applications under development by Sensyne Health in collaboration
with the University of Oxford and Oxford University Hospitals NHS
Foundation Trust. Anonymised data from these systems, can be made
available for analysis by the Company, using its Clinical AI
capabilities for the purposes of medical research and to improve
patient care.
Bini Ajay, Consultant Obstetrician & Gynaecologist at
Croydon Health Services NHS Trust commented: "We start our large
pilot of GDm-Health in October and, having seen its success in
other Trusts, hope our experience will inform a decision to endorse
it for widespread NHS use."
Dr Lucy Mackillop, Consultant Obstetric Physician at Oxford
University Hospitals NHS Foundation Trust and Honorary Senior
Clinical Lecturer, Nuffield Department of Women's and Reproductive
Health, University of Oxford; and the clinical lead for the
development of GDm-Health commented: "I am delighted that
GDm-Health has made the transition to a commercial product and is
available for implementation across the NHS. This is as a result of
an enormous amount of work by the clinical and academic teams at
Oxford University Hospitals NHS Foundation Trust and University of
Oxford and by Sensyne Health to have taken our prototype and
transformed it into a sustainable scalable product."
Lord (Paul) Drayson, CEO of Sensyne Health, commented: "The
overwhelming positive response to GDm-Health from the NHS and from
women with gestational diabetes is testament to its clinically led
design and the fact it is technology that is addressing an area of
urgent, clinical need. We look forward to its wider adoption in the
coming months."
-ENDS-
References
(1) Development of a Real-Time Smartphone Solution for the
Management of Women With or at High Risk of Gestational Diabetes -
J Diabetes Sci Technol 2014 vol. 8 no.
Notes to editors:
About GDM
Gestational diabetes mellitus (GDM) is defined as new onset or
recognition of glucose intolerance in pregnancy which resolves
following birth. Current evidence supports tight blood glucose
control to prevent adverse maternal and foetal outcomes1.
Finger-prick blood glucose testing with frequent clinic review is
the most common method of managing diabetes in pregnancy. GDM is
increasing in prevalence world-wide driven by demographic and
lifestyle changes. In the UK, the rise is predicted to reach over
16%, from a baseline of around 4% in 20081. GDM is usually managed
by women recording their blood glucose results in paper diaries,
typically 6 times a day with regular review by doctors and midwives
in clinic. This manual process is time-consuming and is open to the
risk of transcription errors.
About GDm-Health(TM)
GDm-Health is a direct patient-to-clinician blood glucose
monitoring management system specifically designed for the
management of gestational diabetes and can be used to manage women
with pre-existing diabetes. The system allows clinician review of
patient-annotated blood glucose results in real time. It is based
on a smartphone application that enables women to connect a blood
glucose meter to their smartphone using Bluetooth or NFC (near
field communication) and then automatically collecting blood
glucose measurements. These measurements, along with any text-based
commentary the woman wishes to record, are transmitted directly to
the clinical team where they may be reviewed via a web-based
software application. As a result, clinicians get more time to
focus on the woman's care needs rather than collecting and
recording data and have the ability to prioritise care to women
most at need. The system enables at a glance oversight of the
patient cohort and improves communication with the women in their
care.
GDm-Health is a remote communications device that allows
patients to record and share data with their healthcare team.
GDm-Health does not itself provide any medical diagnosis or advice
or direct patient care. Instead, it provides a patient's healthcare
team with the patient's data in a more easily readable format,
which facilitates the healthcare team's clinical decision-making
and communication back to women under their care, as evidenced by
the results presented in Mackillop L. et al, JMIR Mhealth Uhealth
2018;6(3):e71.
GDm-Health is a CE approved Class 1 medical device that complies
with the essential
Requirements of the European Medical Directive and subsequent
implementing legislation. GDm-Health is listed on NHS Digital's
Apps Library and has been the subject of a NICE (National Institute
for Health and Care Excellence) Medtech innovation briefing
[MIB131].
For more information please contact:
Sensyne Health
Laura Steward
T: +44 (0) 330 058 1845 | M: +44 (0)7899 061975
E: laura.steward@sensynehealth.com
Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
T: +44 20 3709 5700
E: sensynehealth@consilium-comms.com
www.consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that
creates value from accelerating the discovery and development of
new medicines and improving patient care through the analysis of
real-world evidence from large databases of anonymised patient data
in collaboration with NHS Trusts. These anonymised patient data are
ethically sourced in that any analysis of anonymised patient data
(and hence the Company's access to it) must be pre-approved for
each programme on a case-by-case basis by the relevant NHS Trusts.
This is to ensure that the purpose of the anonymisation and the
proposed analysis are subject to appropriate ethical oversight and
information governance, including conformance with NHS principles,
UK data protection law and applicable regulatory guidance. Sensyne
Health is an early signatory to the Department of Health and Social
Care's 'Initial Code of Conduct for data-driven health and care
technology'.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMMMGGKZGRZZ
(END) Dow Jones Newswires
October 16, 2018 02:01 ET (06:01 GMT)
Sensyne Health (LSE:SENS)
Historical Stock Chart
From Apr 2024 to May 2024
Sensyne Health (LSE:SENS)
Historical Stock Chart
From May 2023 to May 2024